Tennessee's 2028 PBM-ownership ban forces choice of divestiture, litigation, or closure

Summary

Tennessee’s 2028 ban on pharmacy benefit manager ownership of retail pharmacies creates a structural decision point for CVS Health, which must choose among litigation, divestiture, or closure of its 134 Tennessee retail locations
The bipartisan coalition behind the Tennessee statute frames the prescription-drug supply chain as no longer functioning as a free market, drawing on a 40-state attorneys general letter that characterized PBMs as “market-dominating behemoths”
Court rulings on Arkansas’s 2025 statute and Tennessee’s 2028 statute will set precedent for the multistate cascade; the 2028 effective date converts litigation delay into a divestiture deadline
A documented mechanism gap remains: ownership severance does not directly regulate the reimbursement and steering practices the law’s proponents identify as the underlying problem, and CVS Caremark could in theory continue to shape pharmacy choice through plan design

Tennessee’s General Assembly has joined Arkansas and a multistate cascade with a bill, signed into law and effective in 2028, that bars companies owning pharmacy benefit managers from also owning retail pharmacies, with bipartisan votes in both chambers and with CVS Health — whose reported holdings span the CVS Caremark PBM, the CVS Pharmacy chain, the Aetna insurer, and 134 Tennessee stores — as the primary reported target. CVS has filed suit in state court, modeled its opposition on the Arkansas fight that delayed a comparable 2025 statute, committed $7 million to a Tennessee television advertising campaign, and texted customers urging contact with lawmakers; the company has neither divested nor closed any Tennessee store as of October 2026. The federal track runs in parallel, with Sens. Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.) sponsoring the Senate version and U.S. Rep. Diana Harshbarger (R-Tenn.), a pharmacist and the mother of state bill lead Sen. Bobby Harshbarger, sponsoring the House version.

The structural choice before CVS Health

The published reporting documents three paths CVS could take under the Tennessee statute: litigation, divestiture, or closure. CVS has filed suit in state court. The company has run a $7 million television campaign and sent text messages to Tennessee customers asking them to contact lawmakers — tactics the article reports helped kill a comparable bill in Louisiana last year. The Tennessee bill’s 2028 effective date functions as a backstop, converting any litigation delay into a divestiture deadline, and CVS has so far taken none of the three structural options.

CVS spokesperson Phil Blando framed the company’s position in three on-record statements: “Any proposed reform should be evaluated based on whether it improves access to care, simplifies the patient experience, and enhances affordability”; “looking at the price of a single prescription does not reflect the value of a comprehensive pharmacy benefit”; and the company’s “focus remains delivering the lowest possible cost and the greatest overall value for members and plan sponsors.” The published reporting does not record which path CVS would prefer under either state law; does not examine whether closure is operationally credible at the $400 billion revenue scale CVS reported last year; and does not test state senators’ implied operational claim that the closure threat is overstated.

Sponsors of the legislation said closure was not the only option. State Sen. Rusty Crowe (R-Tenn.), in urging colleagues to support the bill, said: “I learned when I was in the Vietnam War, when you start taking on flak, you know you’re over the damn target.” State Rep. Antonio Parkinson (D-Memphis), on the Democratic side: “If there’s a benefit to my people, I’m supporting it.” The published reporting does not document which path CVS’s Tennessee operations are most likely to take under each legal outcome.

A bipartisan coalition and its unifying frame

The Tennessee bill drew bipartisan votes in both chambers despite Republican majorities. The published reporting attributes the cross-party alignment to a shared framing of the prescription-drug market as no longer functioning as a free market. Antonio Ciaccia, CEO of 46brooklyn Research, attributed the Republican shift to recognition within the GOP that “We know what competition is supposed to do, and it isn’t happening” — a perception Ciaccia summarized as “This is not a free market.” Barak Richman, a lawyer and economist at George Washington University, characterized healthcare policy more broadly: “We have wildly passionate partisan divides on a lot of healthcare. But there’s a lot of healthcare policy that I don’t think is obviously partisan.”

State Sen. Bobby Harshbarger (R-Tenn.), a pharmacist from northeastern Tennessee who led the bill, articulated the framing in a February legislative hearing: “If a corporation argues that its pharmacy cannot survive unless it is owned by the same entity that sets the reimbursement rate, then we’re not talking about a free market. We’re talking about control.” Last year, attorneys general from nearly 40 states and U.S. territories wrote to congressional leaders arguing that “horizontal consolidation and vertical integration have transformed PBMs from useful administrative service providers into market-dominating behemoths.”

The published reporting presents the Josephs, a Tennessee couple married for 35 years, as illustrating the bipartisan convergence at the household level. Amye Joseph (Republican), on why she and her husband have aligned on this issue: “We hate CVS. I’m going to be straight-up.” She described the company’s role as: “They’re not even a middleman. They’re a money grab for CVS.” Her husband Charlie (Democrat, retired fire captain) reported saving money on his blood pressure medication by paying cash at his local pharmacy for a 90-day supply rather than using his CVS Caremark drug plan for a 30-day supply: “Right now, it’s more of an inconvenience than anything else as far as it goes, but there’s no consistency. The whole healthcare thing is just frustrating, on a good day.” The published reporting does not test whether the Josephs’ alignment is representative of the cross-partisan pattern the article documents, or whether their alignment is recent or longstanding.

The documented three-front fight

The published reporting records CVS preparing to fight on each of three fronts: courtrooms, advertising markets, and customer inboxes. The Tennessee state-court filing challenges the statute; the Arkansas statute, passed in 2025, is being held up in court after CVS challenged its constitutionality. The published reporting does not record the substantive grounds of the Arkansas challenge — commerce clause, takings, due process — beyond the term “constitutionality.” The Arkansas litigation functions as a near-term analog for Tennessee: if the Arkansas challenge succeeds on constitutional grounds, the Tennessee challenge gains a precedent; if it fails, the litigation runway shortens for CVS.

In the advertising market, CVS committed $7 million to a Tennessee television campaign; in customer communications, the company sent text messages to Tennessee customers asking them to contact their lawmakers. Greg Lopes, a spokesperson for the Pharmaceutical Care Management Association, which represents PBMs nationwide, attributed the industry’s position to a manufacturer-PBM “cage match” — the term used by Richman — though the conflict is reported through PCMA’s voice rather than through a direct manufacturer statement. Lopes framed PCMA’s position as: “PBMs are the only part of the prescription drug supply chain working to lower drug costs, which makes PBMs the target of powerful groups, Big Pharma and pharmacists,” and “Drug manufacturers attempt to shift blame for high drug costs to PBMs in order to retain their profit margins and weaken PBMs’ ability to lower costs.”

What happens next

The first observable signal that the cascade is unfolding as anticipated would be a voluntary CVS divestiture announcement, which would convert the 2028 effective date from a deadline into a negotiating instrument. The first observable signal that the cascade is not unfolding as anticipated would be a court stay or strike of either the Tennessee or Arkansas statute before CVS is forced to choose among the documented litigation, divestiture, and closure paths.

In the immediate term (through end of 2026), state-court proceedings on the Tennessee statute and parallel challenges in Arkansas will define the next coverage moments, alongside CVS’s television campaign and continued customer text outreach. The 2026–2028 window will turn on court rulings and the company’s decision on whether to divest, close, or maintain integration while appealing. If state statutes survive court review, CVS faces a structural choice with consequences for plan sponsors, Medicare Part D contracts, and benefit designs that assumed integrated PBM-retail structures; independent pharmacies gain a protected competitive position within affected states; and multistate adoption would apply pressure to restructure nationally rather than state by state.

In the medium term, the cascade would extend to Express Scripts (Cigna) and OptumRx (UnitedHealth Group) — the other two vertically integrated PBM-pharmacy owners — if CVS Caremark is divested under terms that disadvantage it relative to those competitors. Their response, whether pre-emptive structural separation, coordinated industry pushback through PCMA, or quiet compliance, is the next coverage gap. Manufacturer-PBM negotiating leverage would shift if CVS Caremark’s share weakens.

In the longer term, pharmacy benefit designs could be re-priced, manufacturer list pricing could adjust, and the differential between PBM-administered and cash-pay prices could narrow or widen depending on the post-divestiture structure. Charlie Joseph’s reported finding — a 30-day CVS Caremark plan costing more than a 90-day cash supply at his local pharmacy — is one observable empirical signal the divestiture would or would not resolve.

The mechanism gap and the untested hypothesis

A documented gap remains between what the law targets and what its proponents describe as the underlying problem. Ownership severance bars the structural arrangement the article describes; it does not, on the published record, directly regulate the reimbursement and steering practices independent pharmacists describe as the underlying problem. CVS Caremark, post-divorce, could in theory continue to shape patient pharmacy choice through plan design — a mechanism the law’s text does not address.

The hypothesis that vertical integration produces non-competitive outcomes remains untested in the markets affected by these laws. CVS has not divested or closed pharmacies in either state; both laws have yet to take effect. Tennessee legislative researchers, as reported by NPR, concluded the bill could drive up healthcare costs in the short term. The published reporting does not record the methodology, time horizon, or comparator of that finding. If short-term costs rise before long-term competition adjusts pricing, the legislative coalition could weaken before the 2028 effective date.

The published reporting does not adjudicate between Ciaccia’s “not a free market” framing and Lopes’s “PBMs are lowering costs” framing; both appear without resolution. Sen. Bobby Harshbarger framed the bill as a test of whether the prescription drug market remains a free market; the published reporting does not establish which characterization better describes the market structure.

Coverage gaps

The published reporting does not record the substantive grounds of the Arkansas constitutional challenge; the methodology, time horizon, or comparator of the Tennessee legislature’s research finding on short-term cost increases; which restructuring path CVS would prefer under either state law; Express Scripts’s or OptumRx’s response to parallel legislative pressure; whether federal Senate and House sponsors have aligned on a statute-versus-study path; or whether the Josephs’ partisan alignment is representative of the cross-partisan pattern the article documents. Plan sponsors — employers and unions contracting with CVS Caremark — are referenced only through Blando’s statement about “members and plan sponsors” but not separately analyzed; patient populations served by the 134 CVS pharmacies are referenced only as a closure count, with continuity-of-care considerations not analyzed for those on complex regimens or those whose local pharmacy options are limited.

The next observable moments are the court calendar, the 2028 effective date, and any further statehouse vote in the wave the article describes — a wave the Tennessee bill is one data point in. Whether the law produces lower drug prices, more independent pharmacies, or a more fragmented litigation landscape will depend on which of the documented consequence paths materializes, and the 2028 horizon makes the answer one the current legislative cycle will not, on its own, supply.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Consequences & Sequels: Plays a decision forward to its first- and second-order consequences.
Interest Mapping: Separates parties’ stated positions from their underlying interests (Fisher & Ury).
Red-Team Assessment: Models a capable adversary probing a plan for the seams they would exploit.